RevTek Capital Announces the 4th Credit Facility for Apex Biologix

PHOENIX - April 10, 2026 - RevTek Capital is pleased to announce a 4th growth capital credit facility for our portfolio company, Apex Biologix. Apex Biologix is a revolutionary force in regenerative medicine.

This credit facility affirms RevTek's strong conviction in Apex Biologix's team, business model, market opportunity, and long-term trajectory. This capital infusion will support Apex Biologix's continued growth and further expansion of its presence.

All growing SaaS and tech-enabled companies with predictable recurring revenue, seeking covenant-light, founder-friendly growth capital, are invited to apply for funding directly at RevTekCapital.com.

About Apex Biologix

Apex Biologix delivers cutting-edge solutions that empower physicians and transform patient care. Founded in 2014, this innovative company has rapidly become a leader in the industry, offering a seamless ecosystem of advanced therapeutic devices and supplies.

At the heart of Apex Biologix's groundbreaking portfolio is the XCELL PRP System, a game-changing solution that delivers unparalleled platelet concentration with breathtaking ease of use. This extraordinary system produces both leukocyte-rich and leukocyte-poor PRP, providing unmatched flexibility for diverse medical applications.

With a relentless focus on innovation, Apex Biologix continues to push the boundaries of regenerative medicine. Its FDA-cleared products, including the XCELL Bone Marrow Concentrating system, showcase the company's commitment to excellence and regulatory compliance.

Apex Biologix's visionary approach extends beyond product development. They offer comprehensive educational workshops and marketing resources to empower practitioners to develop dynamic, engaging regenerative medicine practices. This holistic strategy has propelled Apex Biologix to the forefront of the industry, making it the go-to partner for physicians seeking to harness the transformative power of autologous biologics.

For more information about Apex Biologix and its mission to empower physicians and transform patient care, click here: ApexBiologix.com

About RevTek Capital

RevTek Capital is an Industry-leading capital provider that provides strategic debt financing in tranches of $2M to $20M+ to innovative companies with predictable annual recurring revenue (ARR) of $5M to $75M. The funding is used for sales growth, acquisitions, and infrastructure enhancements to scale operations. Each company's debt structure is customized to its unique accomplishments and circumstances.

RevTek leverages years of experience in lending and entrepreneurship. This enables them to offer customized credit solutions to growing companies with predictable, recurring revenue across the nation. We aim to help entrepreneurs grow their businesses while maximizing enterprise value for owners, management teams, and shareholders. In addition, the professional team at RevTek has many years of experience in marketing and operations, enabling it to understand and assist its clients as they scale.

Key Benefit Summary

• Helping founders realize their vision
• Cost-effective capital for growing tech-enabled companies
• The company leadership retains control
• Repayment is structured into simple and manageable monthly payments
• Faster access to funding - closing in as little as four weeks and follow-on funding in 10 days or less

If you need capital to give your recurring revenue business the next boost it needs to grow, please get in touch with us at RevTekCapital.com.

For further information, please contact:
RevTek Capital
Scott Peters
Founding Partner and CEO
[email protected]
4215 E McDowell Road
Mesa, AZ 85215